H.R. 3884

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Latest

IIB

118th CONGRESS

2d Session

H. R. 3884

IN THE SENATE OF THE UNITED STATES

September 24, 2024

Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions

AN ACT

To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.


1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023.

2.

Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—

(1)

in paragraph (3)(A), by inserting , grant, or cooperative agreement after contract; and

(2)

in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2024 through 2028.

Passed the House of Representatives September 23, 2024.

Kevin F. McCumber,

Clerk.